Target intelligence / Profile preview

Neurogenic locus notch homolog protein 3 (NOTCH3) (NOTCH3)

Target
NOTCH3
Molecular classification
Receptor, Notch family, Transcription factor
01

Overview

Neurogenic locus notch homolog protein 3 (NOTCH3) is a single-pass transmembrane receptor that plays a critical role in cell-fate determination and vascular homeostasis (UniProt: P31689). Upon binding to ligands such as Jagged or Delta-like, the receptor undergoes sequential proteolytic cleavages by ADAM proteases and the gamma-secretase complex, ultimately releasing the Notch intracellular domain (NICD), which translocates to the nucleus to act as a transcriptional regulator (PubMed: 30104714). In healthy tissues, NOTCH3 is predominantly expressed in vascular smooth muscle cells and is essential for the structural integrity of small arteries (NCBI Gene: 4854). Dysregulation of NOTCH3 signaling is a hallmark of several pathologies, most notably CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), a hereditary stroke disorder caused by specific mutations in the receptor's extracellular domain (PubMed: 25118608). Additionally, NOTCH3 is frequently overexpressed in various malignancies, including ovarian, lung, and breast cancers, where it promotes tumor cell survival, epithelial-mesenchymal transition, and chemoresistance (PubMed: 30104714). Therapeutic strategies targeting NOTCH3 include monoclonal antibodies designed to block ligand-receptor interactions and gamma-secretase inhibitors that prevent the activation of the signaling cascade (PubMed: 28701370). Antibody-drug conjugates (ADCs) are also being explored to deliver cytotoxic payloads specifically to NOTCH3-expressing tumor cells (PubMed: 25118608).

Other names
Notch 3CADASILCASILIMF2LMNSCADASIL1
02

Mechanism of action

Monoclonal antibody antagonism, gamma-secretase inhibition, and antibody-drug conjugation

03

Biological functions

Signal transductionCell differentiationCell proliferationVascular smooth muscle cell developmentApoptosisArtery morphogenesis
04

Disease associations

CancerCADASILCardiovascular diseaseOvarian cancerLung cancerBreast cancerT-cell acute lymphoblastic leukemia
05

Safety considerations

Gastrointestinal toxicitySkin toxicityFatigueVascular complications
06

Interacting drugs

Tarextumab

4 more in the full profile.

07

Biomarkers

NOTCH3 protein expressionNOTCH3 gene mutationsNICD levelsHES1 mRNA levelsN3ECD levels

Beyond the preview

Go deeper on Neurogenic locus notch homolog protein 3 (NOTCH3) (NOTCH3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurogenic locus notch homolog protein 3 (NOTCH3) (NOTCH3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call